{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:15:06Z","timestamp":1794035706037,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients diagnosed with T-cell leukemias and T-cell lymphomas (TCLs) still have a poor prognosis and an inadequate response to current therapies, highlighting the need for targeted treatments. We have analyzed the potential therapeutic value of the farnesyltransferase inhibitor, tipifarnib, in 25 TCL cell lines through the identification of genomic and\/or immunohistochemical markers of tipifarnib sensitivity. More than half of the cell lines (60%) were considered to be sensitive. Tipifarnib reduced cell viability in these T-cell leukemia and TCL cell lines, induced apoptosis and modified the cell cycle. A mutational study showed\n                    <jats:italic>TP53<\/jats:italic>\n                    ,\n                    <jats:italic>NOTCH1<\/jats:italic>\n                    and\n                    <jats:italic>DNMT3<\/jats:italic>\n                    to be mutated in 84.6%, 69.2% and 30.0% of sensitive cell lines, and in 62.5%, 0% and 0% of resistant cell lines, respectively. An immunohistochemistry study showed that p-ERK and RelB were associated as potential biomarkers of tipifarnib sensitivity and resistance, respectively. Data from RNA-seq show that tipifarnib at IC\n                    <jats:sub>50<\/jats:sub>\n                    after 72\u2009h downregulated a great variety of pathways, including those controlling cell cycle, metabolism, and ribosomal and mitochondrial activity. This study establishes tipifarnib as a potential therapeutic option in T-cell leukemia and TCL. The mutational state of\n                    <jats:italic>NOTCH1<\/jats:italic>\n                    , p-ERK and RelB could serve as potential biomarkers of tipifarnib sensitivity and resistance.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-63434-5","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T06:04:37Z","timestamp":1587449077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Ruth","family":"Alonso-Alonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufino","family":"Mond\u00e9jar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Garc\u00eda-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Esteve-Codina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Fuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Pedro","family":"Vaqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gualberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Piris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"63434_CR1","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"JO Armitage","year":"1997","unstructured":"Armitage, J. O. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood 89, 3909\u20133918 (1997).","journal-title":"Blood"},{"key":"63434_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"IT-CL Project","year":"2008","unstructured":"Project, I. T.-C. L. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of Clinical Oncology 26, 4124\u20134130 (2008).","journal-title":"Journal of Clinical Oncology"},{"key":"63434_CR3","doi-asserted-by":"crossref","unstructured":"AbouYabis, A. N., Shenoy, P. J., Sinha, R., Flowers, C. R. & Lechowicz, M. J. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematology 2011 (2011).","DOI":"10.5402\/2011\/623924"},{"key":"63434_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","volume":"40","author":"B Coiffier","year":"2014","unstructured":"Coiffier, B. et al. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treatment Reviews 40, 1080\u20131088 (2014).","journal-title":"Cancer Treatment Reviews"},{"key":"63434_CR5","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz, N. et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116, 3418\u20133425 (2010).","journal-title":"Blood"},{"key":"63434_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bjh.12882","volume":"166","author":"K Patrick","year":"2014","unstructured":"Patrick, K. et al. Outcome for children and young people with E arly T\u2010cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. British Journal of Haematology 166, 421\u2013424 (2014).","journal-title":"British Journal of Haematology"},{"key":"63434_CR7","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d\u2019Amore","year":"2015","unstructured":"d\u2019Amore, F. et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 26, v108\u2013v115 (2015).","journal-title":"Annals of Oncology"},{"key":"63434_CR8","doi-asserted-by":"publisher","first-page":"e0177524","DOI":"10.1371\/journal.pone.0177524","volume":"12","author":"R Mondejar","year":"2017","unstructured":"Mondejar, R. et al. Molecular basis of targeted therapy in T\/NK-cell lymphoma\/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines. PloS One 12, e0177524 (2017).","journal-title":"PloS One"},{"key":"63434_CR9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka, K. et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nature Genetics 47, 1304 (2015).","journal-title":"Nature Genetics"},{"key":"63434_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9470","volume":"6","author":"MJ Kiel","year":"2015","unstructured":"Kiel, M. J. et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK\u201aSTAT pathway in Sezary syndrome. Nature Communications 6, 8470 (2015).","journal-title":"Nature Communications"},{"key":"63434_CR11","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3324\/haematol.2014.113696","volume":"100","author":"R Manso","year":"2015","unstructured":"Manso, R. et al. Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas. Haematologica 100, e25\u2013e27 (2015).","journal-title":"Haematologica"},{"key":"63434_CR12","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.3324\/haematol.2015.132837","volume":"100","author":"C P\u00e9rez","year":"2015","unstructured":"P\u00e9rez, C. et al. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica 100, e450 (2015).","journal-title":"Haematologica"},{"key":"63434_CR13","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1182\/blood-2013-05-504308","volume":"123","author":"JP Vaqu\u00e9","year":"2014","unstructured":"Vaqu\u00e9, J. P. et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood 123, 2034\u20132043 (2014).","journal-title":"Blood"},{"key":"63434_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nature Genetics 49, 1211 (2017).","journal-title":"Nature Genetics"},{"key":"63434_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157\u2013163, https:\/\/doi.org\/10.1038\/nature10725 (2012).","journal-title":"Nature"},{"key":"63434_CR16","first-page":"353","volume":"2009","author":"AA Ferrando","year":"2009","unstructured":"Ferrando, A. A. The role of NOTCH1 signaling in T-ALL. ASH Education Program Book 2009, 353\u2013361 (2009).","journal-title":"ASH Education Program Book"},{"key":"63434_CR17","doi-asserted-by":"publisher","first-page":"S205","DOI":"10.3816\/CLM.2009.s.013","volume":"9","author":"T Palomero","year":"2009","unstructured":"Palomero, T. & Ferrando, A. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clinical Lymphoma and Myeloma 9, S205\u2013S210 (2009).","journal-title":"Clinical Lymphoma and Myeloma"},{"key":"63434_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2008-07-166801","volume":"113","author":"S Sulong","year":"2009","unstructured":"Sulong, S. et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood 113, 100\u2013107 (2009).","journal-title":"Blood"},{"key":"63434_CR19","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1182\/blood-2014-04-566687","volume":"124","author":"S Degryse","year":"2014","unstructured":"Degryse, S. et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood 124, 3092\u20133100 (2014).","journal-title":"Blood"},{"key":"63434_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/ng.924","volume":"43","author":"PP Zenatti","year":"2011","unstructured":"Zenatti, P. P. et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nature Genetics 43, 932 (2011).","journal-title":"Nature Genetics"},{"key":"63434_CR21","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1182\/blood-2005-04-1640","volume":"106","author":"BF Goemans","year":"2005","unstructured":"Goemans, B. F. et al. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 106, 3532\u20133537 (2005).","journal-title":"Blood"},{"key":"63434_CR22","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","volume":"97","author":"JE Karp","year":"2001","unstructured":"Karp, J. E. et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97, 3361\u20133369 (2001).","journal-title":"Blood"},{"key":"63434_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1677\/erc.0.0110191","volume":"11","author":"R O\u2019Regan","year":"2004","unstructured":"O\u2019Regan, R. & Khuri, F. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer? Endocrine-Related Cancer 11, 191\u2013205 (2004).","journal-title":"Endocrine-Related Cancer"},{"key":"63434_CR24","first-page":"131","volume":"61","author":"DW End","year":"2001","unstructured":"End, D. W. et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Research 61, 131\u2013137 (2001).","journal-title":"Cancer Research"},{"key":"63434_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2005.04.005","volume":"7","author":"SM Sebti","year":"2005","unstructured":"Sebti, S. M. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 7, 297\u2013300 (2005).","journal-title":"Cancer Cell"},{"key":"63434_CR26","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1200\/JCO.2002.09.116","volume":"20","author":"M Crul","year":"2002","unstructured":"Crul, M. et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. Journal of Clinical Oncology 20, 2726\u20132735 (2002).","journal-title":"Journal of Clinical Oncology"},{"key":"63434_CR27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2000.18.4.927","volume":"18","author":"J Zujewski","year":"2000","unstructured":"Zujewski, J. et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. Journal of Clinical Oncology 18, 927\u2013927 (2000).","journal-title":"Journal of Clinical Oncology"},{"key":"63434_CR28","unstructured":"Luger, S. et al. (American Society of Hematology, 2012)."},{"key":"63434_CR29","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1182\/blood-2011-02-334904","volume":"118","author":"TE Witzig","year":"2011","unstructured":"Witzig, T. E. et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood 118, 4882\u20134889 (2011).","journal-title":"Blood"},{"key":"63434_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1517\/13543781003801076","volume":"19","author":"PK Epling-Burnette","year":"2010","unstructured":"Epling-Burnette, P. K. & Loughran, T. P. Jr Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opinion on Investigational Drugs 19, 689\u2013698 (2010).","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"63434_CR31","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2174\/1568026033452050","volume":"3","author":"M Venet","year":"2003","unstructured":"Venet, M., End, D. & Angibaud, P. Farnesyl protein transferase inhibitor ZARNESTRA\u2122 R115777-History of a discovery. Current Topics in Medicinal Chemistry 3, 1095\u20131102 (2003).","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"63434_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","volume":"33","author":"JR Cortes","year":"2018","unstructured":"Cortes, J. R. et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell 33, 259\u2013273 e257, https:\/\/doi.org\/10.1016\/j.ccell.2018.01.001 (2018).","journal-title":"Cancer Cell"},{"key":"63434_CR33","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences 102, 15545\u201315550 (2005).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"63434_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research 28, 27\u201330 (2000).","journal-title":"Nucleic acids research"},{"key":"63434_CR35","doi-asserted-by":"publisher","first-page":"D590","DOI":"10.1093\/nar\/gky962","volume":"47","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M., Sato, Y., Furumichi, M., Morishima, K. & Tanabe, M. New approach for understanding genome variations in KEGG. Nucleic acids research 47, D590\u2013D595 (2019).","journal-title":"Nucleic acids research"},{"key":"63434_CR36","first-page":"e74","volume":"32","author":"NPC Zing","year":"2018","unstructured":"Zing, N. P. C., Fischer, T., Zain, J., Federico, M. & Rosen, S. T. Peripheral T-cell lymphomas: Incorporating new developments in diagnostics, prognostication, and treatment into clinical practice\u2014PART 1: PTCL-NOS, FTCL, AITL, ALCL. Oncology 32, e74\u2013e82 (2018).","journal-title":"Oncology"},{"key":"63434_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.10","volume":"5","author":"J Xiong","year":"2015","unstructured":"Xiong, J. et al. Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-\u0152\u00b1 and therapeutic targeting. Blood Cancer Journal 5, e287 (2015).","journal-title":"Blood Cancer Journal"},{"key":"63434_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4161\/cbt.208","volume":"2","author":"WR Bishop","year":"2003","unstructured":"Bishop, W. R., Kirschmeier, P. & Baum, C. Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation. Cancer Biology & Therapy 2, 95\u2013103 (2003).","journal-title":"Cancer Biology & Therapy"},{"key":"63434_CR39","first-page":"303","volume":"9","author":"G Martinelli","year":"2008","unstructured":"Martinelli, G., Iacobucci, I., Paolini, S. & Ottaviani, E. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. Clinical Advances in Hematology and Oncology 9, 303\u2013310 (2008).","journal-title":"Clinical Advances in Hematology and Oncology"},{"key":"63434_CR40","doi-asserted-by":"publisher","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","volume":"272","author":"DB Whyte","year":"1997","unstructured":"Whyte, D. B. et al. K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. Journal of Biological Chemistry 272, 14459\u201314464 (1997).","journal-title":"Journal of Biological Chemistry"},{"key":"63434_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269\u2013271, https:\/\/doi.org\/10.1126\/science.1102160 (2004).","journal-title":"Science"},{"key":"63434_CR42","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3324\/haematol.2015.130179","volume":"100","author":"C Vicente","year":"2015","unstructured":"Vicente, C. et al. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica 100, 1301\u20131310 (2015).","journal-title":"Haematologica"},{"key":"63434_CR43","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.3390\/ijms20123021","volume":"20","author":"E Follini","year":"2019","unstructured":"Follini, E., Marchesini, M. & Roti, G. Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia. International Journal of Molecular Sciences 20, 3021 (2019).","journal-title":"International Journal of Molecular Sciences"},{"key":"63434_CR44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","volume":"126","author":"TE Witzig","year":"2015","unstructured":"Witzig, T. E. et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood 126, 328\u2013335 (2015).","journal-title":"Blood"},{"key":"63434_CR45","doi-asserted-by":"publisher","first-page":"108726","DOI":"10.1016\/j.cbi.2019.108726","volume":"310","author":"W Xu","year":"2019","unstructured":"Xu, W. et al. Tetrandrine and cepharanthine induce apoptosis through caspase cascade regulation, cell cycle arrest, MAPK activation and PI3K\/Akt\/mTOR signal modification in glucocorticoid resistant human leukemia Jurkat T cells. Chemico-Biological Interactions 310, 108726 (2019).","journal-title":"Chemico-Biological Interactions"},{"key":"63434_CR46","doi-asserted-by":"publisher","first-page":"32493","DOI":"10.1074\/jbc.C300226200","volume":"278","author":"AF Castro","year":"2003","unstructured":"Castro, A. F., Rebhun, J. F., Clark, G. J. & Quilliam, L. A. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin-and farnesylation-dependent manner. Journal of Biological Chemistry 278, 32493\u201332496 (2003).","journal-title":"Journal of Biological Chemistry"},{"key":"63434_CR47","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1101\/gad.1690808","volume":"22","author":"KJ Mavrakis","year":"2008","unstructured":"Mavrakis, K. J. et al. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes & Development 22, 2178\u20132188 (2008).","journal-title":"Genes & Development"},{"key":"63434_CR48","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1172\/JCI26833","volume":"117","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga, P. P. et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. The Journal of Clinical Investigation 117, 823\u2013834 (2007).","journal-title":"The Journal of Clinical Investigation"},{"key":"63434_CR49","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/PL00000802","volume":"58","author":"F Tamanoi","year":"2001","unstructured":"Tamanoi, F., Gau, C.-L., Jiang, C., Edamatsu, H. & Kato-Stankiewicz, J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cellular and Molecular Life Sciences 58, 1636\u20131649 (2001).","journal-title":"Cellular and Molecular Life Sciences"},{"key":"63434_CR50","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1093\/bioinformatics\/btt203","volume":"29","author":"M Rubio-Camarillo","year":"2013","unstructured":"Rubio-Camarillo, M., G\u00f3mez-L\u00f3pez, G., Fern\u00e1ndez, J. M., Valencia, A. & Pisano, D. G. RUbioSeq: a suite of parallelized pipelines to automate exome variation and bisulfite-seq analyses. Bioinformatics 29, 1687\u20131689 (2013).","journal-title":"Bioinformatics"},{"key":"63434_CR51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"63434_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).","journal-title":"BMC Bioinformatics"},{"key":"63434_CR53","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research 43, e47\u2013e47 (2015).","journal-title":"Nucleic Acids Research"},{"key":"63434_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq. 2. Genome Biology 15, 550 (2014).","journal-title":"Genome Biology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63434-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T04:43:46Z","timestamp":1670301826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63434-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63434"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63434-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"1 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.P. has received lecture fees and advisory committee fees from Janssen, Takeda and Celgene. The rest of the authors declare no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6721"}}